Binds Virus Or Component Thereof Patents (Class 424/159.1)
-
Publication number: 20140234337Abstract: For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.Type: ApplicationFiled: August 9, 2012Publication date: August 21, 2014Applicants: Immortal Spirit Limited, Ostrich Pharma KKInventor: Yasuhiro Tsukamoto
-
Publication number: 20140234336Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Publication number: 20140227290Abstract: Described is a method for increasing the N-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the N-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (OTase) complex, for example, the Leishmania major STT3D protein, in the presence of expression of the host cell genes encoding the endogenous OTase complex.Type: ApplicationFiled: February 17, 2014Publication date: August 14, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Natarajan Sethuraman, Byung-Kwon Choi, Bianka Prinz, Michael Meehl, Terrance Stadheim
-
Patent number: 8795667Abstract: The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.Type: GrantFiled: December 18, 2008Date of Patent: August 5, 2014Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Publication number: 20140212434Abstract: The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector omprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compostions comprising the vaccine vectors.Type: ApplicationFiled: February 2, 2012Publication date: July 31, 2014Applicant: The United States of America, as represented by the Secretary,Department of Health & HumanServicesInventors: Joseph E. Blaney, Jason Paragas, Peter Jahrling, Reed Johnson, Matthias Schnell
-
Patent number: 8790872Abstract: A method of detecting the production of an analyte by cells in a sample, which method comprises: (i) providing an antibody capable of binding to said analyte and a first agent capable of enhancing detection of said analyte, wherein said antibody and said first agent are immobilized on the same support; (ii) contacting said antibody and said agent with a sample of cells; and (iii) detecting binding of said analyte to said antibody thereby detecting the production of an analyte by cells in a sample.Type: GrantFiled: April 29, 2005Date of Patent: July 29, 2014Assignee: Mabtech ABInventors: Staffan Paulie, Sten Braesch-Andersen
-
Publication number: 20140205614Abstract: The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, including neutralizing antibodies against two or more of H1, H2, H3, H5, H7 and H9, such as, for example all of H1, H2, H3, and H5 subtypes, and methods and means for making such antibodies. More specifically, the invention concerns antibodies capable of neutralizing more than one, preferably all, isolates of an influenza A virus subtype.Type: ApplicationFiled: September 13, 2013Publication date: July 24, 2014Applicant: Sea Lane Biotechnologies, LLCInventors: Lawrence Horowitz, Ramesh Bhatt, Arun K. Kashyap
-
Publication number: 20140205615Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 23, 2013Publication date: July 24, 2014Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Patent number: 8784819Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.Type: GrantFiled: September 29, 2010Date of Patent: July 22, 2014Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
-
Patent number: 8784820Abstract: An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.Type: GrantFiled: November 2, 2012Date of Patent: July 22, 2014Inventors: Trai-Ming Yeh, Yung-Chun Chuang
-
Patent number: 8778347Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: November 11, 2009Date of Patent: July 15, 2014Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Publication number: 20140193428Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 4, 2013Publication date: July 10, 2014Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Patent number: 8771698Abstract: Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.Type: GrantFiled: October 26, 2012Date of Patent: July 8, 2014Assignee: Institut National de la Recherche ScientifiqueInventors: Angela Pearson, Luc Bertrand
-
Publication number: 20140186370Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Applicants: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY, KYOWA HAKKO KIRIN CO., LTD.Inventors: SHINICHIRO KATO, STEVE GRANGER, SHANE CROTTY, SANDRA RICKERT, LILIA KORIAZOVA, TOMOYUKI TAHARA
-
Patent number: 8765132Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: April 16, 2013Date of Patent: July 1, 2014Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20140178405Abstract: Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.Type: ApplicationFiled: December 3, 2013Publication date: June 26, 2014Applicant: Instituto Nacional De Tecnologia Agropecuaria (Inta)Inventors: Thomas SURREY, Aurelien OLICHON, Lorena Laura GARAICOEACHEA, Gisela Ariana MARCOPPIDO, Gladys Viviana PARREÑO, Silvia GÓMEZ SEBASTIÁN, José Angel MARTÍNEZ ESCRIBANO, Andrés WIGDOROVITZ
-
Publication number: 20140170163Abstract: Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicant: MOUNT SINAI SCHOOL OF MEDICINEInventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang
-
Patent number: 8753648Abstract: The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.Type: GrantFiled: December 16, 2005Date of Patent: June 17, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Falko-Guenter Falkner, Georg Holzer, Sogue Coulibaly, Josef Mayrhofer
-
Publication number: 20140161822Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.Type: ApplicationFiled: November 12, 2013Publication date: June 12, 2014Applicant: Genentech, Inc.Inventors: Min XU, Mercedesz BALAZS, Ning CHAI, Nancy Chiang, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
-
Patent number: 8747856Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.Type: GrantFiled: May 4, 2010Date of Patent: June 10, 2014Assignee: Ribovax Biotechnologies S.A.Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
-
Publication number: 20140154265Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.Type: ApplicationFiled: September 24, 2013Publication date: June 5, 2014Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
-
Patent number: 8734803Abstract: Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.Type: GrantFiled: September 28, 2009Date of Patent: May 27, 2014Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Yoko Shoji
-
Publication number: 20140127227Abstract: Provided are stable protein formulations that contain at least one amino acid. In certain embodiments, amino acid combinations either at least two, or three, or four, or more amino acids are included. By virtue of inclusion of the amino acids, the formulation has low viscosity and a protein in the formulations is physically, chemically, and biological stable even at high concentrations. In further embodiments, by virtue of inclusion of the amino acids, a protein in the formulations is physically, chemically, and biological stable even at high concentrations.Type: ApplicationFiled: October 26, 2012Publication date: May 8, 2014Inventor: Byeong Seon Chang
-
Patent number: 8715638Abstract: The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19, R22, R23, and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.Type: GrantFiled: August 19, 2009Date of Patent: May 6, 2014Assignees: Merck Sharp & Dohme Corp., Southern Research InstituteInventors: Cecil D. Kwong, F. George Njoroge, Subramaniam Ananthan, Jeremy Clark, Feng Geng, Hollis S. Kezar, III, Joseph A. Maddry, John J. Piwinski, Robert C. Reynolds, Abhijit Roychowdhury, John A. Secrist, III, Neng-Yang Shih
-
Publication number: 20140120113Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.Type: ApplicationFiled: July 12, 2012Publication date: May 1, 2014Applicant: Crucell Holland B.V.Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
-
Publication number: 20140099299Abstract: The present invention provides methods and compositions for treating and/or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus IL-10 protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10.Type: ApplicationFiled: March 27, 2012Publication date: April 10, 2014Applicant: UAB Research FoundationInventors: Mark R. Walter, Peter A. Barry
-
Patent number: 8691223Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.Type: GrantFiled: December 9, 2011Date of Patent: April 8, 2014Assignee: Crucell Holland B.V.Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
-
Publication number: 20140093500Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.Type: ApplicationFiled: September 27, 2013Publication date: April 3, 2014Applicant: MEDIMMUNE LIMITEDInventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
-
Publication number: 20140093518Abstract: Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.Type: ApplicationFiled: August 26, 2013Publication date: April 3, 2014Applicant: The Scripps Research InstituteInventor: Carlos F. Barbas, III
-
Publication number: 20140072575Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.Type: ApplicationFiled: September 13, 2013Publication date: March 13, 2014Applicant: MedImmune LimitedInventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
-
Patent number: 8669047Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.Type: GrantFiled: July 21, 2011Date of Patent: March 11, 2014Assignee: Theranos, Inc.Inventors: Elizabeth A. Holmes, Ian Gibbons
-
Publication number: 20140065165Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: October 10, 2013Publication date: March 6, 2014Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Publication number: 20140065166Abstract: The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.Type: ApplicationFiled: April 9, 2013Publication date: March 6, 2014Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.Inventors: Christopher C. Broder, Deborah L. Fusco, Kai Hu, Dimitar B. Nikolov
-
Patent number: 8663950Abstract: The present invention describes the plant-based production of a therapeutic antibody against West Nile Virus.Type: GrantFiled: January 10, 2011Date of Patent: March 4, 2014Assignee: Arizona Board of RegentsInventors: Qiang Chen, Huafang Lai
-
Publication number: 20140056913Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.Type: ApplicationFiled: July 25, 2013Publication date: February 27, 2014Applicant: Massachusetts Institute of TechnologyInventors: Ram Sasisekharan, Luke Nathaniel Robinson, Kannan Tharakaraman
-
Publication number: 20140056914Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: ApplicationFiled: September 30, 2013Publication date: February 27, 2014Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20140044719Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.Type: ApplicationFiled: September 10, 2013Publication date: February 13, 2014Applicant: Crucell Holland B.V.Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Koegh
-
Publication number: 20140037648Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.Type: ApplicationFiled: March 14, 2013Publication date: February 6, 2014Applicant: HUMABS BIOMED SAInventor: HUMABS BIOMED SA
-
Publication number: 20140030224Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.Type: ApplicationFiled: April 10, 2012Publication date: January 30, 2014Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
-
Patent number: 8637645Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides for the diagnosis and surveillance of dangerous viral infections.Type: GrantFiled: September 13, 2012Date of Patent: January 28, 2014Assignee: Temasek Life Sciences Laboratory LimitedInventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
-
Patent number: 8637035Abstract: Provided herein are monoclonal antibodies specific to dengue virus as well as their antigen-binding fragments, and functional variants. Also disclosed are uses thereof for treating or diagnosing dengue virus infection.Type: GrantFiled: July 14, 2011Date of Patent: January 28, 2014Assignee: Academia SinicaInventors: Han-Chung Wu, Pi-Chun Li, Mei-Ying Liao, Chien-Yu Chiu
-
Publication number: 20140017257Abstract: A method for large-scale production of anti-NoV antibodies for use as a potential treatment for NoV disease using passive immunization. NoV-specific immunoglobulins (IgY) can be produced by immunizing chickens with NoV P particles. The birds continuously produced high titers of antibodies in their eggs for at least 3 months, in which NoV-specific antibody levels reached 4.7-9.2 mg/egg yolk. The egg yolk antibodies strongly reacted with NoV P particles by both ELISA and Western blot and blocked NoV virus-like particle (VLP) and P particle binding to the histo-blood group antigen (HBGA) receptors with a BT50 of about 1:800. The chicken IgY remain stable at 70° C. for 30 min or treatment at pH 4 to 9 for 3 hr, demonstrating that chicken IgY provides large-scale production of anti-NoV antibodies for use in passive immunization against NoV infection.Type: ApplicationFiled: March 15, 2013Publication date: January 16, 2014Inventors: Xi JIANG, Ying-Chun Dai
-
Patent number: 8623370Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof.Type: GrantFiled: October 6, 2008Date of Patent: January 7, 2014Assignees: Kyowa Hakko Kirin Co., Ltd., La Jolla Institute for Allergy and ImmunologyInventors: Shinichiro Kato, Steve Granger, Shane Crotty, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara
-
Publication number: 20140004111Abstract: The present invention relates to polycyclic antiviral compounds, and salts thereof, methods for their preparation and compositions containing them, and the use of the compounds and composition in the treatment of viral infections.Type: ApplicationFiled: August 30, 2013Publication date: January 2, 2014Applicant: Biota Scientific Management Pty Ltd.Inventors: Jeffrey Peter Mitchell, Alistair George Draffan, Vanessa Anne Sanford, Silas Bond, Chin Yu Lim, Anne Mayes
-
Patent number: 8617808Abstract: The invention provides a method for detecting the production of one or more analytes by cells in a sample. The method uses one or more immobilized binding proteins to capture one or more analytes released from cells. The, or each, binding protein is localized at one or more discrete locations on a solid surface within a well. Cells are introduced into the well and cultured under conditions suitable for release of the analyte(s) and for binding of the analyte(s) to the binding protein(s). Restricting the binding protein(s) to one or more discrete locations within the well, rather than coating the entire surface of the well, results in increased sensitivity of the assay.Type: GrantFiled: April 29, 2005Date of Patent: December 31, 2013Assignee: Mabtech ABInventors: Sten Braesch-Andersen, Staffan Paulie
-
Publication number: 20130330358Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.Type: ApplicationFiled: February 22, 2012Publication date: December 12, 2013Inventors: Jae Jung, Hye-Ra Lee, Myung Hee Kim, Tae-Kwang Oh, Jung-Won Hwang
-
Patent number: 8603480Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: July 15, 2009Date of Patent: December 10, 2013Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 8597651Abstract: Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunization method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.Type: GrantFiled: July 24, 2008Date of Patent: December 3, 2013Assignee: Instituto Nacional de Tecnologia Agropecuaria (INTA)Inventors: Thomas Surrey, Aurelien Olichon, Lorena Laura Garaicoeachea, Gisela Ariana Marcoppido, Gladys Viviana Parreño, Silvia Gómez Sebastián, José Angel Martinez Escribano, Andrés Wigdorovitz
-
Publication number: 20130315929Abstract: A method of identification and elimination of immunodominant epitopes to elicit a response to secondary epitopes, especially conserved structures, is described, and applied to influenza haemagglutinin (HA). Identification of the primary epitopes in (HA), and replacement of amino acids having high LODrps with corresponding low LODrps amino acids produces an HA molecule which induces antibody responses to conserved HA residues. Modified HA molecules induce a broadly neutralizing vaccine.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Inventor: Susan C. Bock
-
Publication number: 20130309248Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: ApplicationFiled: May 20, 2013Publication date: November 21, 2013Inventors: Mark Throsby, Robert H.E. Friesen, Theodorus H.J. Kwaks, Mandy A. C. Jongeneelen